14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
XNCR vs IMVT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Immunovant, Inc. (IMVT) captures the overall head-to-head institutional edge over Xencor, Inc. (XNCR) on higher Unified Composite conviction (39.6/100 SELL vs. 29.6/100 SELL) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while XNCR wins 4–2 across the 6-pillar growth and valuation breakdown. XNCR trades at $35.61 (68.0x Forward P/E, -72.7% operating margin) versus IMVT at $33.30 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: IMVT earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. XNCR 29.6/100 SELL) and 1.74β · 72% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both XNCR (29.6/100 SELL) and IMVT (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on XNCR vs IMVT. Trailing 12-month operating profitability (XNCR -72.7% vs IMVT 0.0%) and valuation multiples (XNCR 68.0x vs IMVT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $7.3B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ XNCR vs IMVT Key Questions & Quantitative Answers
As of Nov 16, 2026, Immunovant, Inc. (IMVT) captures the overall head-to-head institutional edge over Xencor, Inc. (XNCR) on higher Unified Composite conviction (39.6/100 SELL vs. 29.6/100 SELL) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while XNCR wins 4–2 across the 6-pillar growth and valuation breakdown. XNCR trades at $35.61 (68.0x Forward P/E, -72.7% operating margin) versus IMVT at $33.30 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: IMVT earns the overall head-to-head edge with a stronger Unified Composite Score (39.6/100 SELL vs. XNCR 29.6/100 SELL) and 1.74β · 72% Vol risk profile, whereas XNCR leads top-line expansion (+454.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although IMVT compares more favorably head-to-head, both XNCR (29.6/100 SELL) and IMVT (39.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
XNCR leads the Growth & Scale pillar: XNCR posts +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin), compared with IMVT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, XNCR generates $200M in USD-normalized revenue versus N/A for IMVT. In operating R&D and SG&A reinvestment, XNCR deploys 30.2% of Rev ($61M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IMVT.
XNCR screens cheaper on headline valuation multiples. XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin), whereas IMVT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against XNCR (-19.9% ROE) versus IMVT (-86.5% ROE) capital efficiency.
In options market volatility and institutional positioning, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.21β · 87% Vol realized risk). By comparison, IMVT carries 54.1% implied volatility (6th %ile, Compressed (<25th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.74β · 72% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.